Overview

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

Status:
Recruiting
Trial end date:
2030-12-30
Target enrollment:
Participant gender:
Summary
Primary end points: This clinical trial is aimed to analyze the effectiveness of Levonorgestrel-Releasing Intrauterine System (LNG-IUS, Mirena®) in the fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma, including pathology response and pregnancy outcome. Second end points: To analyze the appearances of side-effects.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
West China Second University Hospital
Treatments:
Deslorelin
Levonorgestrel
Medroxyprogesterone
Medroxyprogesterone Acetate
Progesterone